Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Capita shares jump on annual profit surge, 2025 guidance

(Sharecast News) - Shares in Capita jumped on Wednesday after the outsourcing group swung to a profit and guided to steady revenues in 2025 following a double-digit decline last year. The company said that adjusted revenues should be "broadly in line with 2024", as growth in the Public Service and Pension Solutions businesses is offset by a weaker performance from the Contact Centre unit, as well as a winding down of the closed book Life & Pensions as it looks to exit that business.

Adjusted revenue was down 8% at £2.4bn in 2024 due to the previous year's contract losses, volume reductions in the Contact Centre division and the cessation of lower-margin service lines.

Reported pre-tax profit totalled £116.6m, compared with a loss of £106.6m in 2023, helped by the disposal of its software business Capita One and environment research firm Fera which both completed last year.

On an adjusted basis, pre-tax profit improved by 22.2% to £50m.

Capita won just £1.51bn of contracts in 2024, just over half of what was achieved in 2023 (£2.95bn), which it said reflected a lower level of contract bidding activity and a focus on improving its cost competitiveness. However, the firm's renewal rate jumped to 92% from 51%.

"Our strategy strengthens our future prospects and confidence in our medium-term targets. We have leading market positions and are a critical supplier to the UK Government. We have long term customer focused relationships that are increasingly moving from transactional to more strategic," said chief executive Adolfo Hernandez.

Shares were up 8% at 13.92p by 0856 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.